kalshi Science and Technology

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jul 1, 2026?

Before Jul 1, 2026
Closes Jul 01, 2026 (13d) 24h volume 15 Open interest 636 Event Will the FDA approve camizestrant for advanced breast cancer?
15%
implied YES probability
-1.0pp 24h

Price history

Last 11 days · High 50% · Low 1% · 7d -60.0pp
50%1%

Recent news mentioning this market

Trade on Kalshi

Open on Kalshi
Frenzy Capital does not execute trades on prediction markets — we aggregate public order-book and trading data for analysis.

Prediction market data reflects speculative event probabilities, not guaranteed outcomes. This is not investment advice. See Terms §17.